Dermatological adverse effects with the antimalarial drug mefloquine: A review of 74 published case reports

Clinical and Experimental Dermatology

Volumn 24, Issue 4, 1999, Pages 249-254

  Smith, H R ^a   Croft, A M ^b   Black, M M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b MINISTRY OF DEFENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; MEFLOQUINE; STEROID;

ADULT; AGED; ARTICLE; CHILD; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ADULT; AGED; ANTIMALARIALS; CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; MEFLOQUINE; SKIN DISEASES, VASCULAR; STEVENS-JOHNSON SYNDROME; URTICARIA; VASCULITIS;

EID: 0032791480     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.1999.00471.x     Document Type: Article

References (37)

1. 1 Desjardins RE, Pamplin CL, von Bredow J et al. Kinetics of a new antimalarial, mefloquine. Clin Pharmacol Ther 1979; 26: 372-9.
2. 2 Webster LT. Drugs used in the chemotherapy of protozoal infections. In: Goodman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics 8th edn. New York: McGraw-Hill, 1992.
3. 3 Murphy GS, Oldfield EC. Falciparum malaria. Infect Dis Clin North Am 1996; 10: 747-55.
4. 4 Bradley DJ, Warhurst DC. Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Rep Rev 1997; 7: R137-52.
5. 5 Lobel Ho Kozarsky PE. Update on prevention of malaria for travelers. J Am Med Assoc 1997 278 1767-71.
6. 6 Choo V. Uncertainty about mefloquine will take time to resolve. Lancet 1996; 347: 891.
7. 7 Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. Br Med J 1997; 315: 1412-6
8. 8 Parris M. I think I'd rather have malaria. Times Weekend Section (London) 1998 April; 4: 1-2.
9. 9 Eaton L. Fly in the ointment. Sunday Times Magazine (London) 1998 May; 10: 24-35.
10. 10 Ekue JMK, Ulrich AM, Rwabwogo-Atenyi J, Sheth UK. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull WHO 1983; 61: 713-8.
11. 11 Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull WHO 1983; 61: 299-305.
12. 12 Harinasuta T, Bunnag D, Lasserre R et al. Trials of mefloquine in vivax and of mefloquine plus 'Fansidar' in falciparum malaria. Lancet 1985; i: 885-8.
13. 13 De Souza JM, Sheth UK, Wernsdorfer WH et al. A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria. Bull WHO 1987; 65: 357-61.
14. 14 Navaratnam V, Mohamad M, Hussain S et al. Chemosuppression of malaria by the triple combination mefloquine/sulfadoxine/pyrimethamine: a field trial in an endemic area in Malaysia. Trans Roy Soc Trop Med Hyg 1989; 83: 755-9.
15. 15 Ajana F, Fortier B, Mortinot A et al. Prophylaxie par mefloquine et neurotoxicité. À propos d'une observation. Semaine Des Hōpitaux Paris 1990; 66: 918-9.
16. 16 Shlim DR. Severe facial rash associated with mefloquine. J Am Med Assoc 1991; 266: 2560.
17. 17 Suriyamogkol V, Timsaad S, Shanks GD. Mefloquine chemoprophylaxis of soldiers on the Thai-Cambodian border. Southeast Asian J Trop Med Public Health 1991; 22: 515-8.
18. 18 Van den Enden E, van Gompel A, Colebunders R, van Den Ende J. Mefloquine-induced Stevens-Johnson syndrome. Lancet 1991; 337: 683.
19. 19 Doumbo O, Doucoure O, Koita O et al. Efficacité et tolerance de la triple association méfloquine + pyrimethamine + sulfadoxine (Fansimef®) dans la traitement des accès palustres graves à Plasmodium falciparum au Mali (à propos de 100 cas). Médecine D'afrique Noire 1992; 39: 458-62.
20. 20 Looareesuwan S, Viravan C, Vanijanonta S et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992; 339: 821-4.
21. 21 Martin GJ, Malone JL, Ross EV. Exfoliative dermatitis during malarial prophylaxis with mefloquine. Clin Infect Dis 1993; 16: 341-2.
22. 22 Scerri L, Pace JL. Mefloquine-associated cutaneous vasculitis. Int J Dermatol 1993; 32: 517-8.
23. 23 Luxemburger C, ter Kuile FO, Nosten F et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans Roy Soc Trop Med Hyg 1994; 88: 213-7.
24. 24 Croft A. Toxicity of mefloquine is similar to that of other chemoprophylaxis. Br Med J 1995; 311: 191.
25. 25 White AC, Gard DA, Sessoms SL. Cutaneous vasculitis associated with mefloquine. Ann Intern Med 1995; 123: 894.
26. 26 Buma APCC, van Thiel PPAM, Lobel HO et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173: 1506-9.
27. 27 Kollaritsch H, Que JU, Kunz C et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997; 175: 871-5.
28. 28 McBride SR, Lawrence CM, Pape SA, Reid CA. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. Lancet 1997; 349: 101.
29. 29 Ohrt C, Richie TL, Widjaja H et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 963-72.
30. 30 Sowunmi A, Walker O, Salako LA. Pruritus and antimalarial drugs in Africans. Lancet 1989; ii: 213.
31. 31 Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430-75.
32. 32 Miller KD, Lobel HO, Satriale RF et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451-8.
33. 33 Venning GR. Identification of adverse reactions to new drugs. IV Verification of suspected adverse reactions. Br Med 1983; 286: 544-7.
34. 34 Ashby D, Smyth RL, Brown PJ. Statistical issues in pharmacoepidemiological case-control studies. Statist Med 1998; 17: 1839-50.
35. 35 Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. actualisation de la methode utilisée en France. Thérapie 1985; 40: 111-8.
36. 36 Haramburu F, Bégaud B, Péré JC. Comparison of 500 spontaneous and 500 published reports of adverse drug reactions. Eur J Clin Pharmacol 1990; 39: 287-8.
37. 37 Croft AM, Garner P, Squire SB. Malaria prevention for travelers. J Am Med Assoc 1998; 279: 990.